Zealand Pharma A/S (ZEAL.CO)
DKK 802.5
(0.44%)
DKK 802.5
(0.44%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 342.78 Million DKK | 229.65% |
| 2022 | 103.98 Million DKK | -64.46% |
| 2021 | 292.56 Million DKK | -17.19% |
| 2020 | 353.31 Million DKK | 754.8% |
| 2019 | 41.33 Million DKK | 8.84% |
| 2018 | 37.97 Million DKK | -72.83% |
| 2017 | 139.77 Million DKK | -40.47% |
| 2016 | 234.77 Million DKK | 25.1% |
| 2015 | 187.67 Million DKK | 22.05% |
| 2014 | 153.77 Million DKK | 2239.11% |
| 2013 | 6.57 Million DKK | -97.06% |
| 2012 | 223.56 Million DKK | 57.13% |
| 2011 | 142.28 Million DKK | 62.88% |
| 2010 | 87.35 Million DKK | 245.03% |
| 2009 | 25.31 Million DKK | -55.0% |
| 2008 | 56.26 Million DKK | -6.11% |
| 2007 | 59.92 Million DKK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 34.13 Million DKK | 126.2% |
| 2024 Q1 | 15.08 Million DKK | -35.06% |
| 2023 Q4 | 23.23 Million DKK | -92.14% |
| 2023 FY | 342.78 Million DKK | 229.65% |
| 2023 Q2 | 10.4 Million DKK | -23.64% |
| 2023 Q3 | 295.51 Million DKK | 2739.6% |
| 2023 Q1 | 13.62 Million DKK | -43.04% |
| 2022 Q2 | 28.37 Million DKK | 88.19% |
| 2022 Q4 | 23.92 Million DKK | -45.27% |
| 2022 FY | 103.98 Million DKK | -64.46% |
| 2022 Q1 | 15.07 Million DKK | -72.09% |
| 2022 Q3 | 43.71 Million DKK | 54.06% |
| 2021 Q4 | 54.01 Million DKK | -49.24% |
| 2021 Q1 | 47.81 Million DKK | -24.52% |
| 2021 Q3 | 106.4 Million DKK | 26.19% |
| 2021 FY | 292.56 Million DKK | -17.19% |
| 2021 Q2 | 84.32 Million DKK | 76.34% |
| 2020 FY | 353.31 Million DKK | 754.8% |
| 2020 Q2 | 221.01 Million DKK | 1679.95% |
| 2020 Q3 | 56.52 Million DKK | -74.42% |
| 2020 Q4 | 63.35 Million DKK | 12.08% |
| 2020 Q1 | 12.41 Million DKK | 8.04% |
| 2019 Q3 | 9.92 Million DKK | -50.19% |
| 2019 Q4 | 11.49 Million DKK | 15.83% |
| 2019 FY | 41.33 Million DKK | 8.84% |
| 2019 Q1 | - DKK | -100.0% |
| 2019 Q2 | 19.91 Million DKK | 0.0% |
| 2018 Q2 | 15.13 Million DKK | 39.77% |
| 2018 FY | 37.97 Million DKK | -72.83% |
| 2018 Q1 | 10.82 Million DKK | -3.96% |
| 2018 Q4 | 13.11 Million DKK | 0.0% |
| 2018 Q3 | - DKK | -100.0% |
| 2017 Q2 | 10.8 Million DKK | -86.08% |
| 2017 FY | 139.77 Million DKK | -40.47% |
| 2017 Q3 | 40.07 Million DKK | 271.03% |
| 2017 Q4 | 11.27 Million DKK | -71.87% |
| 2017 Q1 | 77.61 Million DKK | -57.0% |
| 2016 Q4 | 180.5 Million DKK | 355.98% |
| 2016 Q1 | 6.51 Million DKK | -96.1% |
| 2016 FY | 234.77 Million DKK | 25.1% |
| 2016 Q3 | 39.58 Million DKK | 398.19% |
| 2016 Q2 | 7.94 Million DKK | 22.02% |
| 2015 Q2 | 7.06 Million DKK | 11.39% |
| 2015 FY | 187.67 Million DKK | 22.05% |
| 2015 Q1 | 6.33 Million DKK | 0.57% |
| 2015 Q4 | 167.1 Million DKK | 2230.64% |
| 2015 Q3 | 7.17 Million DKK | 1.54% |
| 2014 Q3 | 58.17 Million DKK | 1254.89% |
| 2014 Q2 | 4.29 Million DKK | -94.95% |
| 2014 Q1 | 84.99 Million DKK | 2576.23% |
| 2014 FY | 153.77 Million DKK | 2239.11% |
| 2014 Q4 | 6.3 Million DKK | -89.17% |
| 2013 Q3 | 2.31 Million DKK | 114.63% |
| 2013 Q2 | 1.08 Million DKK | 0.0% |
| 2013 Q1 | - DKK | 0.0% |
| 2013 FY | 6.57 Million DKK | -97.06% |
| 2013 Q4 | 3.17 Million DKK | 37.01% |
| 2012 Q3 | 37.36 Million DKK | -43.31% |
| 2012 FY | 223.56 Million DKK | 57.13% |
| 2012 Q4 | - DKK | -100.0% |
| 2012 Q1 | 120.28 Million DKK | 439.01% |
| 2012 Q2 | 65.91 Million DKK | -45.2% |
| 2011 Q3 | 670 Thousand DKK | -99.44% |
| 2011 Q1 | - DKK | -100.0% |
| 2011 FY | 142.28 Million DKK | 62.88% |
| 2011 Q4 | 22.31 Million DKK | 3230.75% |
| 2011 Q2 | 119.29 Million DKK | 0.0% |
| 2010 Q1 | - DKK | 0.0% |
| 2010 Q4 | 3.72 Million DKK | 376.6% |
| 2010 Q3 | 782 Thousand DKK | -99.06% |
| 2010 Q2 | 82.84 Million DKK | 0.0% |
| 2010 FY | 87.35 Million DKK | 245.03% |
| 2009 FY | 25.31 Million DKK | -55.0% |
| 2008 FY | 56.26 Million DKK | -6.11% |
| 2007 FY | 59.92 Million DKK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ALK-Abelló A/S | 4.82 Billion DKK | 92.894% |
| Bavarian Nordic A/S | 7.05 Billion DKK | 95.143% |
| Genmab A/S | 16.47 Billion DKK | 97.919% |
| Gubra A/S | 205 Million DKK | -67.21% |
| Novo Nordisk A/S | 232.26 Billion DKK | 99.852% |
| Orphazyme A/S | - DKK | -Infinity% |
| Pharma Equity Group A/S | - DKK | -Infinity% |